Melody Abikhair

Melody Abikhair

Auto-generated profile, based on publicly available information

Melody Abikhair

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
MSMary Stevenson
Mary Stevenson
CWClaire Q. F. Wang
Claire Q. F. Wang
MAMelody Abikhair
Melody Abikhair
NRNazanin Roudiani
Nazanin Roudiani
DFDiane Felsen
Diane Felsen
JCJohn A Carucci
John A Carucci
Importance Limited therapies are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC). Objective To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC. Design, Setting, and Participants A single patient with locally advanced cSCC who declined surgery and radiotherapy underwent treatment with pembrolizumab, an anti–PD-1 antibody, at an academic dermatologic surgery section and cancer center. The patient was followed up for clinical and radiologic regression of cSCC. With the use of NanoString to amplify potential biomarkers, immunohistochemistry, and immunofluorescence, the ex vivo expression of PD-1 and a ligand (PD-L2) was assessed in 38 cSCC biopsy specimens from 24 patients with cSCC. Expression of PD-L1 and PD-L2 in the cSCC microenvironment was defined. Intervention Pembrolizumab, 2 mg/kg every 3 weeks, for 4 cycles. Main Outcomes and Measures Expression of PD-L1 and PD-L2 in the cSCC microenvironment. Results In 1 patient with locally advanced cSCC who was treated with pembrolizumab, nearly complete tumor regression was observed after 4 cycles of therapy. The NanoString technology used in 38 cSCC biopsy specimens from 24 patients with cSCC (19 men and 5 women; mean [SD] age, 76.4 [12.2] years) detected increased PD-1 and PD-L2 expression in high-risk cSCC. Immunohistochemical analysis confirmed enhanced expression of PD-1 and its ligands in cSCC with perineural invasion (mean [SEM] expression, 5.06 [1.27];P = .05), superficial cSCC (mean [SEM] expression, 3.58 [1.50];P = .15), organ transplant–associated cSCC (mean [SEM] expression, 3.01 [0.54];P = .005), and infiltrative cSCC (mean [SD] expression, 2.01 [0.30];P = .006) compared with normal skin specimens. In double-label immunofluorescence staining, CD11c+, a marker of myeloid dendritic cells, colocalized with PD-L1 and PD-L2 in cSCC lesions. Conclusions and Relevance The favorable treatment response combined with significant involvement of PD-1 and PD ligands in cSCC lesions suggests that PD-1 blockade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further investigation in future clinical trials.

15 March 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GGGareth Peter Gregory
Gareth Peter Gregory
AAAshwini Arumugaswamy
Ashwini Arumugaswamy
TLTeresa Leung
Teresa Leung
KCKah-Lok Chan
Kah-Lok Chan
MAMelody Abikhair
Melody Abikhair
Stephen OpatStephen Opat
Stephen Opat
The optimal treatment strategy in patients with aggressive B cell central nervous system lymphoma suitable to receive intensive therapy is unknown. The benefit of incorporating rituximab in systemic therapy remains unclear. We performed a retrospective study examining the impact of rituximab in the context of concomitant therapies, including methotrexate, cytarabine, and radiotherapy, in patients treated with curative intent at 4 university teaching hospitals during 1996–2011. A retrospective study of CNS lymphoma cases treated at the participating institutions was performed in accordance with institutional ethical guidelines. Patients were included if they received a diagnosis of primary diffuse large B cell lymphoma of the CNS, were HIV negative, and were treated with curative intent. One hundred twenty patients aged 21–81 years were identified. Rituximab recipients and nonrecipients were similar, except for rituximab recipients being more likely to have received a diagnosis after 2004. The median follow-up of surviving patients was 30 months. The 5-year overall survival was 46%. Univariate analysis revealed age ≤60 years, ECOG performance status ≤1, normal lactate dehydrogenase, diagnosis after 2004, and treatment with cytarabine and rituximab as predictive of favorable overall survival. Multivariate analysis identified age to be an independent predictor of overall survival, with a trend toward improved survival from the other variables that were significant in univariate analyses. In this retrospective analysis, the addition of rituximab to high-dose methotrexate-based chemotherapy in patients with aggressive B cell CNS lymphoma was associated with improved overall survival. Further studies are underway to prospectively validate these findings.

2 June 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
MAMelody Abikhair
Melody Abikhair
HMHiroshi Mitsui
Hiroshi Mitsui
VYValerie Yanofsky
Valerie Yanofsky
NRNazanin Roudiani
Nazanin Roudiani
COChanna Ovits
Channa Ovits
JCJohn A Carucci
John A Carucci
Immune-suppressed organ transplant recipients (OTRs) can develop catastrophic squamous cell carcinoma (SCC), characterized by multiple primary tumors, extensive body surface area involvement, or metastases. There are currently no curative systemic therapies available. We previously showed that IL-22 enhances SCC proliferation. Herein, we examined links between cyclosporine (CSA), IL-22, and SCC in patients, cell lines, and mice with UV light–induced SCC. Eighteen of 114 OTRs developed catastrophic SCC, which was strongly associated with CSA treatment. We found that CSA drives T cell polarization toward IL-22–producing T22 cells, and CSA treatment increased IL-22 receptor in SCC cells. SCC tissue from OTRs showed increased expression of IL-22RA1. CSA potentiated rescue by IL-22 of serum-starved SCC cells; treatment of SCC cells with IL-22 and CSA increased both their migratory and invasive capacity. In a UV-induced model of SCC in SKH-1 immunocompetent mice, treatment with anti–IL-22 antibody reduced tumor number and tumor burden. We found that catastrophic SCC in OTRs is associated with CSA use, which may be acting by favoring T22 polarization. Since anti–IL-22 antibody administration decreased tumor number and tumor burden in vivo, blockade of the IL-22 axis may be developed as a viable therapeutic option for catastrophic SCC.

6 September 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
MBMelody Abikhair Burgo
Melody Abikhair Burgo
NRNazanin Roudiani
Nazanin Roudiani
JCJie Chen
Jie Chen
ASAlexis Santana
Alexis Santana
NDNicole Doudican
Nicole Doudican
JCJohn A Carucci
John A Carucci
Organ transplant recipients (OTRs) on cyclosporine A (CSA) are prone to catastrophic cutaneous squamous cell carcinoma (SCC). Allograft-sparing, cancer-targeting systemic treatments are unavailable. We have shown increased risk for catastrophic SCC in OTRs via CSA-mediated induction of IL-22. Herein, we found that CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction. We in turn inhibited SCC growth with an FDA-approved JAK1/2 inhibitor, ruxolitinib. In human SCC cells, the greatest proliferative response to IL-22 and CSA treatment occurred in nonmetastasizing lines. IL-22 treatment upregulated JAK1 and STAT1/3 in A431 SCC cells. JAK/STAT pathway genes were highly expressed in tumors from a cohort of CSA-exposed OTRs and in SCC with high risk for metastasis. Compared with immunocompetent SCC, genes associated with innate immunity, response to DNA damage, and p53 regulation were differentially expressed in SCC from OTRs. In nude mice engrafted with human A431 cells, IL-22 and CSA treatment increased tumor growth and upregulated IL-22 receptor, JAK1, and STAT1/3 expression. Ruxolitinib treatment significantly reduced tumor volume and reversed the accelerated tumor growth. CSA and IL-22 exacerbate aggressive behavior in SCC. Targeting the IL-22 axis via selective JAK/STAT inhibition may reduce the progression of aggressive SCC in OTRs, without compromising immunosuppression.

5 November 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
MAMelody Abikhair
Melody Abikhair
NRNazanin Roudiani
Nazanin Roudiani
HMHiroshi Mitsui
Hiroshi Mitsui
JKJames G. Krueger
James G. Krueger
APAnna Pavlick
Anna Pavlick
JCJohn A Carucci
John A Carucci

3 February 2014 in Medical Journal of Australia
Verified
Journal Article
Closed access
MAMelody R Abikhair
Melody R Abikhair
PMPatrick D Mahar
Patrick D Mahar
ACAdrian R Cachia
Adrian R Cachia
JKJohn W Kelly
John W Kelly
Doctors may be liable for failing to diagnose atypical presentations of melanoma